Financials
Financial year 2025
MEDSYS from Gembloux, company number BE0450817990, closed financial year 2025 with a result of € 87,987 after tax. For that financial year MEDSYS recorded a gross margin of € 170,272 and equity of € 239,662. Compared with financial year 2024, the result moved from € 42,535 to € 87,987. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.
€ 239,662
▼ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 87,987
▲ 107% vs 2024
Profit after tax over the fiscal year.
€ 153,557
▲ 78% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 123,491 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 81,843
▼ 42% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 24,002
▼ 47% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,514
▲ 64% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 179,270 | € 130,565 | € 183,064 | € 170,272 | ▼ 7% |
| Profit after taxes | € -48,752 | € -68,894 | € 42,535 | € 87,987 | ▲ 107% |
| Equity | € 301,525 | € 232,631 | € 275,166 | € 239,662 | ▼ 13% |
| Total debts | € 97,296 | € 28,445 | € 55,055 | € 164,007 | ▲ 198% |
| Cash | € 232,124 | € 41,172 | € 86,132 | € 153,557 | ▲ 78% |
| Retained profit | € 101,525 | € 32,631 | € 75,166 | € 39,662 | ▼ 47% |
| Dividend | € 53,052 | € 0 | € 0 | € 123,491 | |
| Balance sheet total | € 398,821 | € 261,076 | € 330,221 | € 403,669 | ▲ 22% |
Key figures of MEDSYS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDSYS?
What happened at MEDSYS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 87,987 (▲ 107% vs 2024). Source: NBB ↗
- Trandium SRL became a director. NBB
- Tanguy Bertrand became a director. NBB
- New establishment in Gembloux. KBO
- Start of the company according to the CBE. KBO
In short
From € 48,752 loss in 2022 to € 87,987 profit in 2025.
Paid € 2,512 in corporate taxes since 2022.
Best year ever: 2025, with € 87,987 profit.
Paid out € 176,543 in dividends to the owners in total.
Management
The stake of GUALIMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
MEDSYSBehind MEDSYS are Trandium SRL and Tanguy Bertrand. The shares are held by GUALIMA (100%).
Directors
According to the 2025 annual accounts
Managing director · represented by Marie Bertrand
Also active at: SURGICAL INSTRUMENTS BELGIUM, GUALIMA
since 2024
since 2024
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue du Gaillard,Sauv. 3
5030 Gembloux
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0450.817.990
- VAT number
- BE 0450.817.990
- Registered office
- Rue du Gaillard,Sauv. 3, 5030 Gembloux
- Names & denominations
- MEDSYS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 7 September 1993
- Peppol
- Active · Active since 19 Dec 2025
- Activities · NACE
Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden
Vervaardiging van niet-elektrische apparaten en instrumenten voor de geneeskunde, de tandheelkunde en de veeartsenijkunde